Literature DB >> 7688553

Deletion of chromosome 11 and of 14q sequences in neuroblastoma.

E S Srivatsan1, K L Ying, R C Seeger.   

Abstract

Restriction fragment length polymorphism (RFLP) analysis carried out on 45 primary neuroblastomas showed deletion of chromosome 11 sequences in 12 of 37 (32%) informative cases. Both 11p and 11q probes were informative in seven tumors; loss of all of chromosome 11, of only 11p sequences, and of only 11q sequences was observed in 4, 1, and 2 tumors, respectively. A cytogenetic abnormality involving translocation of chromosome arm 11q to chromosome arm 1p was observed in a primary tumor. Deletion of 14q was observed in 6 of 27 (22%) informative cases. Deletion of chromosome 11 but not 14q may correlate with regional and metastatic disease. These results suggest a possible role for sequences localized to chromosome 11 and to 14q in the development and/or progression of neuroblastoma.

Entities:  

Mesh:

Year:  1993        PMID: 7688553     DOI: 10.1002/gcc.2870070106

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

1.  Immunohistochemical detection of p140trkA and p75LNGFR neurotrophin receptors in neuroblastoma.

Authors:  C Dominici; M R Nicotra; S Alemà; C Bosman; M A Castello; A Donfrancesco; P Gallo; H McDowell; P G Natali
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 2.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  Fine mapping of an imprinted gene for familial nonchromaffin paragangliomas, on chromosome 11q23.

Authors:  B E Baysal; J E Farr; W S Rubinstein; R A Galus; K A Johnson; C E Aston; E N Myers; J T Johnson; R Carrau; S J Kirkpatrick; D Myssiorek; D Singh; S Saha; S M Gollin; G A Evans; M R James; C W Richard
Journal:  Am J Hum Genet       Date:  1997-01       Impact factor: 11.025

4.  Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.

Authors:  D Plantaz; G Mohapatra; K K Matthay; M Pellarin; R C Seeger; B G Feuerstein
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

5.  Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.

Authors:  Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera
Journal:  Virchows Arch       Date:  2008-06-24       Impact factor: 4.064

6.  The genomic and transcriptomic landscape of a HeLa cell line.

Authors:  Jonathan J M Landry; Paul Theodor Pyl; Tobias Rausch; Thomas Zichner; Manu M Tekkedil; Adrian M Stütz; Anna Jauch; Raeka S Aiyar; Gregoire Pau; Nicolas Delhomme; Julien Gagneur; Jan O Korbel; Wolfgang Huber; Lars M Steinmetz
Journal:  G3 (Bethesda)       Date:  2013-08-07       Impact factor: 3.154

7.  Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines.

Authors:  R A Jesudasan; R A Rahman; S Chandrashekharappa; G A Evans; E S Srivatsan
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

8.  Bioinformatics analysis of recurrent deletion regions in neuroblastoma.

Authors:  Hasan Onur Caglar
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

9.  Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.

Authors:  Rani E George; Edward F Attiyeh; Shuli Li; Lisa A Moreau; Donna Neuberg; Cheng Li; Edward A Fox; Matthew Meyerson; Lisa Diller; Paolo Fortina; A Thomas Look; John M Maris
Journal:  PLoS One       Date:  2007-02-28       Impact factor: 3.240

10.  An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas.

Authors:  O Takeda; M Handa; T Uehara; N Maseki; A Sakashita; M Sakurai; N Kanda; Y Arai; Y Kaneko
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.